araag2/HINT huggingface dataset:
Clinical trial NCT02903251 (phase 3, status: completed)
Conditions: alcoholism, substance-related disorders
ICD codes: Z63.72, F19.14, F19.180, F19.182, F19.188, F19.19, F19.24, F19.280
Drugs: intranasal oxytocin spray
SMILES: [H][C@@]1(C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)O[C@H]1[C@H](C)[C@@H](O[C@]2([H])O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@@H]1C)OC
Eligibility criteria:

        Inclusion Criteria:

          1. At least one prior episode 2 days or longer in duration during which the subject
             experienced withdrawal symptoms that caused significant incapacitation (e.g.,
             inability to work or do normal activities) OR at least one prior inpatient or
             outpatient medical detoxification during which the subject exhibited withdrawal
             symptoms of sufficient magnitude that sedative-hypnotic or anticonvulsant medication
             was required at least once on 2 consecutive days after cessation of or reduction in
             the use of alcohol following 2 weeks or more of heavy daily consumption

          2. average consumption of 8-30 standard drinks per day for at least 2 weeks prior to
             enrollment in the study;

          3. consenting to participate in the study;

          4. have residency in Trøndelag County after discharge

        Exclusion Criteria:

          1. chronic treatment with sedative-hypnotic medications such as benzodiazepines or
             z-hypnotics;

          2. dependence on substances other than alcohol, nicotine or caffeine;

          3. inadequately treated, unstable and/or compromising medical or psychiatric conditions;

          4. low body weight (BMI < 17) or history of anorexia nervosa or bulimia in the past 2
             years;

          5. pregnancy; parturition or breast-feeding in the past 6 months;

          6. inability to read well enough to complete study questionnaires determined by whether
             the prospective subject can read the consent form without help and correctly answer
             basic questions about information in the consent form;

          7. no alcohol in the blood and > 15 h since last intake of alcohol;

          8. prior inclusion and participation in the same study.
Clinical trial NCT02906722 (phase 3, status: terminated)
Conditions: ventilator-associated pneumonia
ICD codes: J95.851
Drugs: intravenous colimycin, intravenous placebo, nebulized colimycin, nebulized placebo
SMILES: CC[C@]1(O)C[C@@H]2CN(C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=C(OC)C=C2N(C=O)[C@@H]3[C@]4(CCN5CC=C[C@](CC)([C@@H]45)[C@@H](OC(C)=O)[C@]3(O)C(=O)OC)C2=C1, [Na+].[Cl-], CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    lack of inclusion
  
Eligibility criteria:

        Inclusion criteria

          -  Age older than 18 yr

          -  Invasive mechanical ventilation for more than 48 h Tracheostomized patients receiving
             intermittent mechanical ventilation can be included

          -  VAP caused by Gram-negative MDR bacteria resistant to all β-lactams and
             fluoroquinolones

        Exclusion criteria

          -  Extrapulmonary Gram-negative MDR infection requiring intravenous colimycin

          -  VAP associated with bacteremia requiring combined treatment by nebulized and
             intravenous colimycin

          -  Hypersensitivity to colistimethate, colistin base, polymyxins and/or their excipients

          -  Porphyria

          -  Severe hypoxemia defined as PaO2 / FiO2< 100; if veno-venous ECMO is initiated, the
             patient can be included

          -  Severe brain injury (initial Glasgow coma score < 8) during the first 7 days before
             randomization

          -  Myasthenia

          -  cystic fibrosis

          -  Refusal to participate in the study

          -  Participation in any clinical study of a therapeutic investigational product within 30
             days prior to the first day of inclusion

          -  No affiliation to social health insurance

          -  Patient under guardianship

          -  Pregnancy
Clinical trial NCT02913326 (phase 3, status: completed)
Conditions: thromboembolism
ICD codes: O88.22, O88.23, O88.211, O88.212, O88.213, O88.219
Drugs: dabigatran etexilate, warfarin
SMILES: CCCCCCOC(=O)\N=C(\N)C1=CC=C(NCC2=NC3=C(C=CC(=C3)C(=O)N(CCC(=O)OCC)C3=NC=CC=C3)N2C)C=C1, S1SSSSSSS1
Eligibility criteria:

        Inclusion criteria:

          -  Written informed consent in accordance with International Conference on Harmonization
             (ICH) Good Clinical Practice (GCP) guidelines and local legislation and/or regulations

          -  Confirmed diagnosis of Cerebral Venous or dural sinus thrombosis (CVT), with or
             without intracranial haemorrhage

          -  Completion of anticoagulation therapy for 5-15 days which has been administered until
             randomisation; anticoagulation must include full-dose low molecular weight heparin or
             unfractionated heparin

          -  Eligibility for treatment with an oral anticoagulant

          -  Further inclusion criteria apply

        Exclusion criteria:

          -  Cerebral Venous or dural sinus thrombosis (CVT) associated with central nervous system
             infection or due to head trauma

          -  Planned surgical treatment for CVT

          -  Conditions associated with increased risk of bleeding

          -  History of symptomatic non-traumatic intracranial haemorrhage with risk of recurrence
             according to Investigator judgment

          -  Treatment with an antithrombotic regimen for an indication other than CVT and
             requiring continuation of that treatment for the original diagnosis without change in
             the regimen

          -  Severe renal impairment

          -  Active liver disease

          -  Pregnancy, nursing or planning to become pregnant while in the trial

          -  Further exclusion criteria apply
Clinical trial NCT02914509 (phase 3, status: completed)
Conditions: open angle glaucoma, ocular hypertension
ICD codes: H40.10X0, H40.10X1, H40.10X2, H40.10X3, H40.10X4, H40.1130, H40.1131, H40.053, H40.051, H40.052, H40.059
Drugs: travoprost
SMILES: CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COC1=CC=CC(=C1)C(F)(F)F
Eligibility criteria:

        Inclusion Criteria:

          -  Documented diagnosis of ocular hypertension with an open angle of Schaffer Grade 3 or
             greater or open-angle glaucoma without pseudoexfoliation or pigment dispersion or
             evidence of traumatic angle recession

          -  IOP is currently controlled as assessed by the Investigator

        Exclusion Criteria:

          -  Punctum size smaller than 0.4 mm or greater than 0.9 mm in either eye as measured
             using a standard punctum gauge

          -  A history of an inadequate response or no response to topical prostaglandin

          -  Known or suspected allergy and/or hypersensitivity to travoprost or any prostaglandin,
             fluorescein, or to any component of the study products
Clinical trial NCT02916602 (phase 3, status: completed)
Conditions: hypertension
ICD codes: I15.0, I97.3, K76.6, P29.2, G93.2, H40.053, I10
Drugs: hcp1401, hcp0605
SMILES: CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1, CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1
Eligibility criteria:

        Inclusion Criteria:

          -  Hypertension patient who satisfied below condition at Visit 1.

               -  patient who takes antihypertensive drug

                    -  140mmHg <= sitSBP <= 200mmHg

               -  patient who doesn't take antihypertensive drug

                    -  160mmHg <= sitSBP <= 200mmHg

                    -  140mmHg <= sitSBP <= 200mmHg at Visit 2

        Exclusion Criteria:

          -  Patient who have received 4 or more antihypertensive drug

          -  Patient with 20mmHg of difference in sitSBP or 10mmHg of difference in sitDBP between
             3 times of BP measuring at Visit 1

          -  Patient with sitDBP >= 120mmHg at Visit 2

          -  Patient with secondary hypertension
Clinical trial NCT02923921 (phase 3, status: completed)
Conditions: pancreatic cancer
ICD codes: C25.3
Drugs: folfox
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          1. The presence of metastatic pancreatic adenocarcinoma

          2. Measurable disease per RECIST v.1.1

          3. Participant must have documented tumor progression during or following a gemcitabine
             containing regimen to treat metastatic disease as established by CT or MRI scan

          4. Eastern Cooperative Oncology Group Performance Status of 0 - 1

          5. Participant must have completed prior chemotherapy at least 2 weeks (washout period)
             prior to randomization and recovered from toxicity to Grade 1 or baseline

          6. Participants must not have received previous radiation therapy or investigational
             therapy for the treatment of advanced metastatic disease.

          7. Participants having received cytotoxic doses of gemcitabine or any other chemotherapy
             in the adjuvant setting are not eligible for this study

          8. No peripheral neuropathy

          9. No known history of dihydropyrimidine dehydrogenase deficiency

        Exclusion Criteria:

          1. Diagnosis of pancreatic islet neoplasm, acinar cell carcinoma, non- adenocarcinoma
             (i.e., lymphoma, sarcoma), adenocarcinoma originating from the biliary tree, or
             cystadenocarcinoma

          2. Participant on Coumadin and not willing to change to LMWH or oral Factor II or Xa
             inhibitor with half-life of less than 24 hours.

          3. Participant has received prior treatment with pegilodecakin or
             fluoropyrimidine/platinum containing regimen

          4. Participants who were intolerant of a gemcitabine containing regimen.

          5. History of positivity for human immunodeficiency virus

          6. Chronic active or active viral hepatitis A, B, or C infection

          7. Clinically significant bleeding within two weeks prior to randomization (e.g.,
             gastrointestinal (GI) bleeding, intracranial hemorrhage)

          8. Pregnant or lactating women

          9. Participants with a history of immune-mediated neurological disorders such as multiple
             sclerosis, Guillain-Barré or inflammatory CNS/PNS disorders

         10. Clinically significant ascites defined as requiring ≥ 1 paracentesis every 2- weeks

         11. Major surgery, defined as any surgical procedure that involves general anesthesia and
             a significant incision (i.e., larger than what is required for placement of central
             venous access, percutaneous feeding tube, or biopsy),within 28 days prior to
             randomization or anticipated surgery during the study period

         12. Prior history of receiving immune modulators including, but not limited to,
             anti-CTLA4, anti-PD1, anti-PD-L1
Clinical trial NCT02926898 (phase 3, status: completed)
Conditions: dravet syndrome
ICD codes: G40.833, G40.834
Drugs: zx008 - 0.2 mg/kg/day, zx008 - 0.4 mg/kg/day, zx008 - 20 mg/day maximum dose, matching placebo
SMILES: CC1=CC(O)=CC(C)=C1Cl
Eligibility criteria:

        Key Inclusion Criteria:

          -  Subject must be male or non-pregnant, non-lactating female, age 2 to 18 years
             (inclusive)

          -  Subject must have documented medical history to support a clinical diagnosis of Dravet
             syndrome, where convulsive seizures are not completely controlled by current
             antiepileptic drugs.

          -  Subject must be receiving a therapeutically relevant and stable dose of CLB, VP, and
             STP for at least 4 weeks prior to screening and are expected to remain stable
             throughout the study (Cohort 2 only).

          -  Subject must be receiving a stable dose of CLB and VPA, administered twice daily, to
             be eligible for Dose Regimen 1 and 2 or subject must be receiving a stable dose of
             CLB, VPA, and STP, administered twice daily, to be eligible for Dose Regimen 3 (Cohort
             1 only).

        Key Exclusion Criteria:

          -  Subject has a known hypersensitivity to fenfluramine or any of the excipients in the
             study medication.

          -  Subject has pulmonary arterial hypertension.

          -  Subject has a current or past history of cardiovascular or cerebrovascular disease,
             such as cardiac valvulopathy, myocardial infarction or stroke.

          -  Subject has a current or recent history of anorexia nervosa, bulimia, or depression
             within the prior year that required medical treatment or psychological treatment for a
             duration greater than 1 month.

          -  Subject has a current or past history of glaucoma.

          -  Subject is receiving concomitant therapy with: centrally-acting anorectic agents;
             monoamine-oxidase inhibitors; any centrally-acting compound with clinically
             appreciable amount of serotonin agonist or antagonist properties, including serotonin
             re-uptake inhibition; triptans, atomoxetine, or other centrally-acting noradrenergic
             agonist; cyproheptadine, and/or CYP 2D6/3A4/2B6 inhibitors/substrates.

          -  Subject is currently taking carbamazepine, oxcarbamazepine, eslicarbazepine,
             phenobarbital, or phenytoin, or has taken any of these within the past 30 days, as
             maintenance therapy.

          -  Subject has a positive result on urine THC Panel or whole blood CBD at the Screening
             Visit.

          -  Subject has a clinically significant condition, or has had clinically relevant
             symptoms or a clinically significant illness in the 4 weeks prior to the Screening
             Visit, other than epilepsy, that would negatively impact study participation,
             collection of study data, or pose a risk to the subject.
Clinical trial NCT02932943 (phase 3, status: completed)
Conditions: depressive disorder, major
ICD codes: F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F33.40
Drugs: rapastinel, placebo
SMILES: C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(N)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Meet Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5)
             criteria for MDD

          -  Current major depressive episode of at least 8 weeks and not exceeding 18 months in
             duration at Visit 1

          -  Have no more than partial response (< 50% improvement) to ongoing treatment with a
             protocol-allowed antidepressant

          -  If female of childbearing potential, have a negative serum β-human chorionic
             gonadotropin (β-hCG) pregnancy test.

        Exclusion Criteria:

          -  DSM-5-based diagnosis of any disorder other than MDD that was the primary focus of
             treatment within 6 months before Visit 1

          -  Lifetime history of meeting DSM-5 criteria for:

               1. Schizophrenia spectrum or other psychotic disorder

               2. Bipolar or related disorder

               3. Major neurocognitive disorder

               4. Neurodevelopmental disorder of greater than mild severity or of a severity that
                  impacts the participant's ability to consent, follow study directions, or
                  otherwise safely participate in the study

               5. Dissociative disorder

               6. Posttraumatic stess disorder

               7. MDD with psychotic features

          -  Significant suicide risk, as judged by the Investigator.
Clinical trial NCT02933814 (phase 3, status: withdrawn)
Conditions: pain
ICD codes: N50.82, R07.2, R07.82, R10.13, R10.33, R14.1, R52
Drugs: liposomal bupivicaine
SMILES: CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C
Reason stopped: 
    inadequate number of subjects meet study criteria
  
Eligibility criteria:

        Inclusion Criteria:

          -  Patients 18 years of age and over undergoing ambulatory hand surgery involving soft
             tissue and subfascial structures, including: CMC arthritis, flexor and extensor tendon
             injury, symptomatic ganglia, hand and finger fractures

        Exclusion Criteria:

          -  Patients who are unable to give informed consent to participate in this study

          -  Patients with a documented history of hypersensitivity reactions to local anesthetic
             agents

          -  Patients with a diagnosis of chronic pain disorders such as fibromyalgia, chronic
             migraine headaches, or psychiatric disorders other than depression or anxiety

          -  Patients who are currently pregnant

          -  Patients with impaired hepatic function

          -  Patients with underlying nerve damage or impairment

          -  Patients with renal impairment/failure

          -  Patients whose career/livelihood require a great deal of hand dexterity, in whom a
             complication could cause a significant impact on life and career (ex: musician,
             dentist)
Clinical trial NCT02940860 (phase 3, status: completed)
Conditions: iron deficiency anaemia, iron deficiency anemia, chronic kidney disease
ICD codes: D81.810, E53.0, E53.1, E61.0, E61.1, E61.2, E61.3, D50.9, D50.0, D50.8, I12.9, N18.9, I12.0, D63.1, N18.1, N18.5, I13.0
Drugs: iron isomaltoside/ferric derisomaltose, iron sucrose
SMILES: O.O.O.[OH-].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[Na+].[Na+].[Fe+3].[Fe+3].[Fe+3].[Fe+3].[Fe+3].OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O
Eligibility criteria:

        Inclusion Criteria includes:

          1. Men and women, ≥ 18 years

          2. Hb ≤ 11 g/dL

          3. Chronic renal impairment, as defined by either (i) eGFR < 60 mL/min/1.73m2 at
             screening (as calculated by modification of diet in renal disease (MDRD)), or (ii)
             Estimated Glomerular Filtration Rate (eGFR) < 90 mL/min/1.73m2 at screening and kidney
             damage as indicated by abnormalities in urine composition per medical history and/or
             intermediate/high risk of cardio-vascular disease based on the Framingham model

          4. Screening s-ferritin ≤ 100 ng/mL, or ≤ 300 ng/mL if Transferrin Saturation (TSAT) ≤ 30
             %

          5. Either no Erythropoiesis Stimulating Agent (ESAs) or ESAs as a stable dose 4 weeks
             before randomisation

          6. Willingness to participate and signing the informed consent form

        Exclusion Criteria includes:

          1. Anaemia predominantly caused by factors other than IDA

          2. Hemochromatosis or other iron storage disorders

          3. Previous serious hypersensitivity reactions to any IV iron compounds

          4. Prior to screening or during the trial period; has or will be treated with a red blood
             cell transfusion, radiotherapy, and/or chemotherapy

          5. Undergoing dialysis for treatment of CKD

          6. Planned surgical procedure within the trial period

          7. Decompensated liver cirrhosis or active hepatitis

          8. Alcohol or drug abuse within the past 6 month.

          9. Pregnant or nursing women.
Clinical trial NCT02940886 (phase 3, status: completed)
Conditions: iron deficiency anaemia, iron deficiency anemia
ICD codes: D81.810, E53.0, E53.1, E61.0, E61.1, E61.2, E61.3, D50.9, D50.0, D50.8
Drugs: iron isomaltoside/ferric derisomaltose, iron sucrose
SMILES: O.O.O.[OH-].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[Na+].[Na+].[Fe+3].[Fe+3].[Fe+3].[Fe+3].[Fe+3].OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O
Eligibility criteria:

        Inclusion criteria includes:

          1. Men or women ≥ 18 years

          2. Subjects having IDA caused by different etiologies

          3. Subjects with intolerance to oral iron therapy or a need for rapid repletion of iron
             stores:

          4. Haemoglobin (Hb) ≤ 11 g/dL

          5. Transferrin Saturation (TSAT) < 20 %

          6. S-ferritin < 100 ng/mL

          7. Willingness to participate and signing the informed consent form

        Exclusion Criteria includes :

          1. Anemia predominantly caused by factors other than IDA

          2. Hemochromatosis or other iron storage disorders

          3. Previous serious hypersensitivity reactions to any IV iron compound

          4. Erythropoiesis stimulating agent (ESA) treatment

          5. Prior to screening or during the trial period; has or will be treated with a red blood
             cell transfusion, radiotherapy, and/or chemotherapy

          6. Will require a surgical procedure that necessitated general anesthesia prior to
             screening or during the trial period

          7. Alanine aminotransferase and/or aspartate aminotransferase > 3 times upper limit of
             normal

          8. Required dialysis for treatment of chronic kidney disease (CKD)

          9. Alcohol or drug abuse within the past 6 months

         10. Pregnant or nursing women
Clinical trial NCT02942004 (phase 3, status: completed)
Conditions: postpartum depression
ICD codes: F53.0
Drugs: placebo, sage-547 60 μg/kg/h, sage-547 90 μg/kg/h
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@]1(CC[C@@]2([H])[C@]3([H])CC[C@@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)C(C)=O, [H][C@@]1(CC[C@@]2([H])[C@]3([H])CC[C@@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)C(C)=O
Eligibility criteria:

        Key Inclusion Criteria:

          -  Participants must have ceased lactating at screening; or if still lactating or
             actively breastfeeding at screening, agreed to temporarily cease giving breastmilk to
             their infant(s) from just prior to receiving study drug through nine days (Day 12)
             after the end of the infusion

          -  Participants had a major depressive episode that began no earlier than the third
             trimester and no later than the first 4 weeks following delivery, as diagnosed by
             Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I)

          -  Participant had a HAM-D total score of ≥26 at screening and Day 1 (prior to dosing)

          -  Participant was ≤6 months postpartum at screening

          -  Participant was amenable to IV therapy

        Key Exclusion Criteria:

          -  Active psychosis

          -  Attempted suicide associated with index case of postpartum depression

          -  Medical history of bipolar disorders, schizophrenia, and/or schizoaffective disorder.

        Note: Other protocol-defined inclusion/exclusion criteria applied.